Halozyme Therapeutics (HALO) executive compensation, 2026 proxy

Helen I. Torley, President and Chief Executive Officer, was paid $23.2M in fiscal 2025, up 82% from $12.7M the year before. The CEO-to-median-employee pay ratio was 100:1, on median employee pay of $231,329.

Filed
March 23, 2026
Annual meeting
May 5, 2026
Pay year
fiscal 2025
Named executives
5
CEO total pay
$23.2M+82% vs prior year
CEO to median employee
100:1median $231,329
CEO pay in equity
91%$21M in awards
Prior say-on-pay support
96%of votes cast
Stock price increase
40%Common stock price growth in 2025
Total revenues
$1,397MIncreased 38% from 2024
Capital returned
$342.3MThrough share repurchases
Royalty revenues
$868MIncreased 52% from 2024

How Torley was paid

$23.2M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary4%Stock awards84%Option awards7%Non-equity incentive5%All other compensation0%

Named executive officers

ExecutiveTotal
Helen I. TorleyPresident and Chief Executive Officer$23,166,223
Nicole LaBrosseSenior Vice President, Chief Financial Officer$4,578,814
Mark SnyderSenior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary$4,531,568
Cortney CaudillSenior Vice President, Chief Operating Officer$3,202,906
Michael J. LaBarreFormer Senior Vice President, Chief Technical Officer$2,053,642

What changed and why

  • $23.2MTotal CEO compensation increased to $23,166,223 in 2025 primarily due to a one-time performance-based equity award.
  • $10MDr. Torley received a one-time performance-based equity award valued at $10,000,012 linked to stock price hurdles.
  • 127.5%Annual cash incentive payouts ranged from 127.5% to 153% of target based on corporate performance.
  • $1,397MTotal revenue reached $1,397 million, representing a 38% increase from the prior fiscal year.
  • $342.3MThe company returned approximately $342.3 million in capital to stockholders through share repurchases.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.